Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Biomarin Pharmaceutical
(NASDAQ:BMRN)
Intraday
$82.19
0.02
[0.02%]
After-Hours
$82.19
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$82.19
0.02
[0.02%]
At close: Apr 25
$82.19
0
[0.00%]
PreMarket: 4:49PM EDT
Get Report
Watch
Q1 2024 Earnings were released on Wed Apr 24th, after the market close
The most recent conference call was at 16:30 PM, 2 days ago
Click to view past webcast
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Biomarin Pharmaceutical Stock (NASDAQ:BMRN)
Biomarin Pharmaceutical Stock (NASDAQ: BMRN)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, April 25, 2024
Citigroup Maintains Neutral on Biomarin Pharmaceutical, Lowers Price Target to $91
Benzinga Newsdesk
-
10 hours ago
Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Avi Kapoor
-
15 hours ago
Deep Dive Into Biomarin Pharmaceutical Stock: Analyst Perspectives (8 Ratings)
Benzinga Insights
-
17 hours ago
Scotiabank Maintains Sector Perform on Biomarin Pharmaceutical, Raises Price Target to $85
Benzinga Newsdesk
-
18 hours ago
Cantor Fitzgerald Reiterates Overweight on Biomarin Pharmaceutical, Maintains $110 Price Target
Benzinga Newsdesk
-
19 hours ago
Wells Fargo Maintains Overweight on Biomarin Pharmaceutical, Raises Price Target to $110
Benzinga Newsdesk
-
19 hours ago
BioMarin Pharmaceutical shares are trading lower after the company reported Q1 financial results.
Benzinga Newsdesk
-
23 hours ago
Wednesday, April 24, 2024
BioMarin Pharmaceutical shares are trading lower after the company reported Q1 financial results.
Benzinga Newsdesk
-
1 day ago
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights
-
1 day ago
Biomarin Pharmaceutical Raises FY2024 Adj EPS Guidance From $2.60-$2.80 To $2.75-$2.95 Vs $1.65 Est; Affirms FY2024 Sales Guidance from $2.70B-$2.80B Vs $2.77B Est
Benzinga Newsdesk
-
1 day ago
Biomarin Pharmaceutical Q1 Adj $0.71 May Not Compare To $0.34 Estimate, Sales $648.83M Miss $651.79M Estimate
Benzinga Newsdesk
-
1 day ago
Wednesday, April 03, 2024
Looking Into Biomarin Pharmaceutical's Recent Short Interest
Benzinga Insights
-
Apr 3, 2024, 2:00PM
Thursday, March 21, 2024
Major Decision: Dennis Slamon Exercises Options, Realizing $50K At Biomarin Pharmaceutical
Benzinga Insights
-
Mar 21, 2024, 11:01AM
Tuesday, March 12, 2024
New Data To Be Presented For BioMarin's VOXZOGO In Children With Hypochondroplasia And Achondroplasia At The American College Of Medical Genetics And Genomics Annual Clinical Genetics Meeting
Benzinga Newsdesk
-
Mar 12, 2024, 8:55AM
Friday, March 08, 2024
Massive Insider Trade At Biomarin Pharmaceutical
Benzinga Insights
-
Mar 8, 2024, 10:03AM
Thursday, February 29, 2024
Canaccord Genuity Reiterates Hold on Biomarin Pharmaceutical, Maintains $91 Price Target
Benzinga Newsdesk
-
Feb 29, 2024, 10:33AM
Monday, February 26, 2024
BioMarin Complied With A U.S. Department Of Justice Subpoena For Documents On Its Testing Programs For VIMIZIM And NAGLAZYME; Cannot Predict Investigation's Outcome Or Its Impact On Its Business Or Financial Statements
Benzinga Newsdesk
-
Feb 26, 2024, 1:52PM
Friday, February 23, 2024
The Latest Analyst Ratings For Biomarin Pharmaceutical
Benzinga Insights
-
Feb 23, 2024, 1:01PM
Cantor Fitzgerald Reiterates Overweight on Biomarin Pharmaceutical, Maintains $100 Price Target
Benzinga Newsdesk
-
Feb 23, 2024, 12:18PM
RBC Capital Reiterates Sector Perform on Biomarin Pharmaceutical, Maintains $100 Price Target
Benzinga Newsdesk
-
Feb 23, 2024, 10:47AM
Thursday, February 22, 2024
Recap: Biomarin Pharmaceutical Q4 Earnings
Benzinga Insights
-
Feb 22, 2024, 4:15PM
Biomarin Pharmaceutical Q4 2023 Adj EPS $0.49 Beats $0.23 Estimate, Sales $646.20M Beat $636.88M Estimate
Benzinga Newsdesk
-
Feb 22, 2024, 4:04PM
Earnings Scheduled For February 22, 2024
Benzinga Insights
-
Feb 22, 2024, 5:27AM
Tuesday, February 06, 2024
BioMarin To Present ROCTAVIAN Data Highlighting Long-Term Durability At 2024 European Association For Haemophilia And Allied Disorders Congress
Benzinga Newsdesk
-
Feb 6, 2024, 8:36AM
Tuesday, January 30, 2024
Decoding 8 Analyst Evaluations For Biomarin Pharmaceutical
Benzinga Insights
-
Jan 30, 2024, 2:00PM
Baird Maintains Outperform on Biomarin Pharmaceutical, Lowers Price Target to $104
Benzinga Newsdesk
-
Jan 30, 2024, 1:38PM
Thursday, December 21, 2023
Cracking The Code: Understanding Analyst Reviews For Biomarin Pharmaceutical
Benzinga Insights
-
Dec 21, 2023, 12:00PM
Stifel Reiterates Buy on Biomarin Pharmaceutical, Maintains $101 Price Target
Benzinga Newsdesk
-
Dec 21, 2023, 11:05AM
Wednesday, December 20, 2023
Biomarin Pharmaceutical Announced Several Initiatives To Enhance Corporate Governance And Long-Term Shareholder Value Creation; Enters Into Cooperation And Information Sharing Agreements With Elliott Investment Management
Benzinga Newsdesk
-
Dec 20, 2023, 4:09PM
Tuesday, November 28, 2023
BioMarin Announces Agreement With German Health Insurance Fund On Reimbursement Amount For ROCTAVIAN For Severe Hemophilia A In Germany
Benzinga Newsdesk
-
Nov 28, 2023, 8:31AM
Wednesday, November 08, 2023
Check Out What Whales Are Doing With BMRN
Benzinga Insights
-
Nov 8, 2023, 12:31PM
Tuesday, November 07, 2023
Activist Investor Elliott Pushes for Strategy Revamp at BioMarin Amid CEO Change
Vandana Singh
-
Nov 7, 2023, 4:12PM
RBC Capital Reiterates Sector Perform on Biomarin Pharmaceutical, Maintains $100 Price Target
Benzinga Newsdesk
-
Nov 7, 2023, 1:09PM
BioMarin Pharmaceuticals shares are trading higher following a report suggesting activist investor Elliott Investment Management has built a stake in the company and has been in talks with the company for months.
Benzinga Newsdesk
-
Nov 7, 2023, 12:16PM
Datadog, Tripadvisor, Myriad Genetics, Planet Fitness And Other Big Stocks Moving Higher On Tuesday
Lisa Levin
-
Nov 7, 2023, 10:54AM
'Activist Investor Elliott Targets Drugmaker BioMarin; Has Spent Over $1B On The Stake In The Co' - Reuters News
Benzinga Newsdesk
-
Nov 7, 2023, 10:34AM
Thursday, November 02, 2023
Piper Sandler Maintains Overweight on Biomarin Pharmaceutical, Lowers Price Target to $115
Benzinga Newsdesk
-
Nov 2, 2023, 4:00PM
BMO Capital Maintains Outperform on Biomarin Pharmaceutical, Lowers Price Target to $100
Benzinga Newsdesk
-
Nov 2, 2023, 2:36PM
Morgan Stanley Maintains Overweight on Biomarin Pharmaceutical, Lowers Price Target to $117
Benzinga Newsdesk
-
Nov 2, 2023, 12:05PM
BioMarin Pharmaceutical shares are trading lower after the company reported worse-than-expected Q3 revenue results and issued FY23 guidance. Additionally, Cantor Fitzgerald and Barclays lowered their respective price targets on the stock.
Benzinga Newsdesk
-
Nov 2, 2023, 11:26AM
Barclays Maintains Overweight on Biomarin Pharmaceutical, Lowers Price Target to $111
Benzinga Newsdesk
-
Nov 2, 2023, 10:59AM
Cantor Fitzgerald Maintains Overweight on Biomarin Pharmaceutical, Lowers Price Target to $100
Benzinga Newsdesk
-
Nov 2, 2023, 9:59AM
Wednesday, November 01, 2023
BioMarin Announces Retirement Of Jean-Jacques Bienaimé; Appoints Alexander Hardy President And Chief Executive Officer
Benzinga Newsdesk
-
Nov 1, 2023, 5:10PM
Biomarin Pharmaceutical Sees FY23 Adj. EPS $1.90-$2.05 vs $1.02 Est., Total Revenues $2.39B-$2.47B vs $2.45B Est.
Benzinga Newsdesk
-
Nov 1, 2023, 5:05PM
Biomarin Pharmaceutical Q3 Adj $0.46 Beats $0.22 Estimate, Sales $581.33M Miss $608.68M Estimate
Benzinga Newsdesk
-
Nov 1, 2023, 5:04PM
Earnings Scheduled For November 1, 2023
Benzinga Insights
-
Nov 1, 2023, 7:19AM
Tuesday, October 31, 2023
Earnings Outlook For Biomarin Pharmaceutical
Benzinga Insights
-
Oct 31, 2023, 1:02PM
Friday, October 27, 2023
Why Is Gene Therapy Player PTC Therapeutics Stock Plunging Today?
Vandana Singh
-
Oct 27, 2023, 1:00PM
Monday, October 23, 2023
Bernstein Upgrades Biomarin Pharmaceutical to Market Perform, Announces $82 Price Target
Benzinga Newsdesk
-
Oct 23, 2023, 5:21AM
Friday, October 20, 2023
FDA Approves BioMarin's VOXZOGO For Children Under 5 Years With Achondroplasia
Benzinga Newsdesk
-
Oct 20, 2023, 4:09PM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch